BioSpace News Archive

Delfi Diagnostics, a pioneering developer of a new class of high-performance, affordable liquid biopsy tests for early cancer detection, added two new leaders to its management team to oversee regulatory, policy, and reimbursement activities as the company advances its products toward commercialization.

WU-NK-101 is a novel immunotherapy harnessing the power of memory natural killer cells to treat liquid and solid tumors.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that results from the pivotal Phase 3 RISE-PD clinical trial evaluating the novel investigational extended-release CD/LD formulation, IPX-203, in Parkinson’s disease patients with motor fluctuations, will be presented at the 2022 American Academy of Neurology (AAN) Annual Meeting, April 2-7, in Seattle, WA.

Imbria Pharmaceuticals, Inc. today announced the appointment of biopharmaceutical industry veteran John Young to its board of directors.

Blade Therapeutics, Inc. today announced that the company will present data for cudetaxestat in three posters at the American Thoracic Society (ATS) 2022 International Conference, May 13-18, 2022, The Moscone Center, in San Francisco.

Tanner Pharma Group, an international distributor of essential medicines, announced that it has significantly increased its inventory of Leukine (sargramostim, yeast-derived rhuGM-CSF) to be held in Europe.

Psilera, Inc. has named Daniel N. Santiago, Ph.D. as the Director and Head of their Computational Chemistry Department. Dr. Santiago’s appointment is vital to continuing the growth of Psilera’s machine learning and artificial intelligence drug discovery platform.

Lineage Cell Therapeutics, Inc. today announced that Brian M. Culley, the Company’s Chief Executive Officer, will be presenting at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest.

EpiEndo Pharmaceuticals is pleased to announce the appointment of Stefan Petursson as Chief Financial Officer (CFO), starting 1 April 2022.

Phosplatin Therapeutics Inc., a clinical stage pharmaceutical company focused on oncology therapeutics, today announced the appointment of Lorenzo Galluzzi, PhD, to the company’s Scientific Advisory Board.